Following nearly two decades of development, significant advancements have been
achieved in PROTAC technology. As of the end of 2022, more than 20 drugs have entered …

Introduction: Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the
balance of acetylation and deacetylation of lysine residues of histones and non-histone …

This review classifies drug‐design strategies successfully implemented in the development
of histone deacetylase (HDAC) inhibitors, which have many applications including cancer …

Histone deacetylases (HDACs) are epigenetic enzymes which participate in transcriptional
repression and chromatin condensation mechanisms by removing the acetyl moiety from …

Inducing protein degradation by proteolysis targeting chimeras has gained tremendous
momentum as a promising novel therapeutic strategy. Here, we report the design, synthesis …

Metal-dependent histone deacetylases (HDACs) are key epigenetic regulators that
represent promising therapeutic targets for the treatment of numerous human diseases. Yet …

Abstract Histone deacetylase 8 (HDAC8) aberrantly deacetylates histone and non-histone
proteins. These include structural maintenance of chromosome 3 (SMC3) cohesin protein …

Class I histone deacetylases (HDACs) are key regulators of cell proliferation and they are
frequently dysregulated in cancer cells. We report here the synthesis of a novel series of …

Class I histone deacetylases (HDACs) are closely associated with the development of a
diverse array of diseases, including cancer, neurodegenerative disorders, HIV, and …

Histone deacetylase (HDAC) is an epigenetic antitumor drug target, but most existing HDAC
inhibitors show limited antitumor activity and their use is often accompanied by serious …